<DOC>
	<DOCNO>NCT02774005</DOCNO>
	<brief_summary>LEROS open-label interventional Phase IV study , design ass efficacy safety Raxone® long-term treatment LHON patient .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Raxone LHON Patients</brief_title>
	<detailed_description />
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Atrophy , Hereditary , Leber</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<criteria>1 . Impaired visual acuity affect eye due LHON 2 . No explanation visual loss besides LHON 3 . Age equal 12 year 4 . Onset symptoms ≤5 year Baseline 5 . Confirmation either G11778A , G3460A T14484C LHON mtDNA ( ITT population , require enrolment ) 6 . Written inform consent obtain patient 7 . Ability willingness comply study procedures visit 8 . Women Childbearing Potential ( WCBP ) negative urine serum pregnancy test Baseline visit willing use highly effective contraceptive measure maintain treatment discontinuation . 1 . Patient provide natural history data Case Record Survey ( SNTCRS002 ) 2 . Any previous use idebenone 3 . Any cause visual impairment ( e.g . glaucoma , diabetic retinopathy , AIDS relate visual impairment , cataract , macular degeneration , etc . ) active ocular disorder ( uveitis , infection , inflammatory retinal disease , thyroid eye disease , etc . ) 4 . Known history clinically significant elevation ( great 3 time upper limit normal ) AST , ALT creatinine 5 . Patient condition situation , investigator 's opinion may put patient significant risk , may confound study result may interfere significantly patient 's participation study 6 . Participation another clinical trial investigational drug within 3 month prior Baseline 7 . Hypersensitivity active substance follow excipients ( list section 6.1 Raxone SmPC ) : Lactose monohydrate , Microcrystalline cellulose , Croscarmellose sodium , Povidone K25 , Magnesium stearate , Colloidal silica , Macrogol 3350 , Poly ( vinyl alcohol ) , Talc , Titanium dioxide , Sunset yellow FCF ( E110 ) . 8 . Women pregnant positive pregnancy test Baseline visit 9 . Women breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>